Lakshmi Iyer, CEO – Investment & Strategy, Kotak Alternate Asset Managers
Kotak Alternate Asset Managers Announces First Close of Kotak Life Sciences Fund
INR 1600 Crore Fund to Invest in Early to Growth Stage Companies across Life Science and Healthcare Segment
Mumbai / Chennai, 23 January 2025: Kotak Alternate Asset Managers Limited (Kotak Alt) today announced the first close of its Life Sciences Fund, Kotak Life Sciences Fund, a Category II AIF private equity fund. The INR 1600 Cr. The fund has announced its first close after collecting INR 250 Cr. from family offices, UHNIs, industry veterans, and institutions alike.
Kotak Life Sciences Fund has a focused strategy and will deploy capital early – to growth-stage companies in life sciences (Pharma/Biotech), medical devices, digital health, consumer wellness, diagnostics and delivery, among others.
Lakshmi Iyer, CEO – Investment & Strategy, Kotak Alternate Asset Managers, said, "We are delighted by the response to the first close of our Life Sciences Fund. As an asset manager, we remain committed to providing our investors and channel partners access to differentiated strategies in line with our structural positive view on various themes. This fundraise across institutions, family offices, UHNIs, and HNIs is a testimony to our solid investment track record built over two decades."
Ashish Ranjan, Director Private Equity, Kotak Alternate Asset Managers, added, "Life Sciences is a core sector where the firm deploys capital across the lifecycle of the company i.e. early, growth and late stage. In the past 24 months, Kotak Alt's has deployed close to INR 4000 Cr. in the segment, across different pools of capital. Kotak Life Sciences Fund will focus on backing companies built for the next 10 years wherein the intent is to support companies in their early days of growth, and the infusion of capital can not only accelerate their progress but also help them differentiate themselves."
Kotak Alts' deep understanding and expertise across the segment stems from its decade long investment track record in healthcare and nuanced understanding of the healthcare ecosystem, thus helping the firm establish its leadership position across the segment.
